Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Eribulin Mesylate Injection
Eribulin · 1 trial · 2 indications
Hair loss rate defined as CTCAE v5.0 alopecia grade 1 or higher compared in the scalp cooling group using the Paxman Hair Loss Prevention System (PSCS) and group not using scalp cooling.
| Arm | Type | Description |
|---|---|---|
| ERIBULIN WITH PAXMAN SCALP COOLING SYSTEM (PSCS) | EXPERIMENTAL | Participants will use Paxman Scalp Cooling System (PSCS) on days 1, 8 and 21 of each of their standard of care (SOC) treatment cycles with Eribulin. Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years. |
| ERIBULIN WITHOUT PAXMAN SCALP COOLING SYSTEM (PSCS) | ACTIVE_COMPARATOR | Participants will not use Paxman Scalp Cooling System (PSCS) during their standard of care (SOC) treatment with Eribulin. Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years. |
| SACITUZUMAB GOVITECAN WITH PAXMAN SCALP COOLING SYSTEM (PSCS) | EXPERIMENTAL | Participants will use Paxman Scalp Cooling System (PSCS) on days 1 and 21 of each of their standard of care (SOC) treatment cycles with SACITUZUMAB GOVITECAN. Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years. |
| SACITUZUMAB GOVITECAN WITHOUT PAXMAN SCALP COOLING SYSTEM (PSCS) | ACTIVE_COMPARATOR | Participants will not use Paxman Scalp Cooling System (PSCS) during their standard of care (SOC) treatment with SACITUZUMAB GOVITECAN. Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years. |
| TRASTUZUMAB DERUXTECAN WITH PAXMAN SCALP COOLING SYSTEM (PSCS) | EXPERIMENTAL | Participants will use Paxman Scalp Cooling System (PSCS) on days 1, 8 and 21 of each of their standard of care (SOC) treatment cycles with TRASTUZUMAB DERUXTECAN. Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years. |
| TRASTUZUMAB DERUXTECAN WITHOUT PAXMAN SCALP COOLING SYSTEM | ACTIVE_COMPARATOR | Participants will not use Paxman Scalp Cooling System (PSCS) during their standard of care (SOC) treatment with TRASTUZUMAB DERUXTECAN. Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years. |
| Name | Type | Description |
|---|---|---|
| Paxman Scalp Cooling System | DEVICE | Cap attached to coolant lines connected to a refrigeration unit placed on scalp |
| Eribulin | DRUG | Intravenous Infusion |
| Sacituzumab govitecan | DRUG | Intravenous Infusion |
| Trastuzumab deruxtecan | DRUG | Intravenous Infusion |
Inclusion Criteria: * Men and women with a diagnosis of metastatic invasive breast cancer with a ECOG PS≤2 * Participant is ≥ 18 years old. * Hair present at baseline. * One of the following full dose chemotherapy regimens must be planned for at least 4 cycles: * Sacituzumab govitecan (IMMU-132)...
Top 20 of 91 competitors
Eribulin is a small molecule oncology drug being studied for use in metastatic breast cancer. It is currently in Phase 2 clinical development as an investigational therapy. Eribulin is administered as an injection and is being evaluated for its effects on patients with this condition.
Eribulin targets tubulin proteins, including TUBB4B, TUBB1, TUBA3C, TUBA4A, TUBB3, and TUBA1A. It acts as an inhibitor of these molecular targets, which are components of microtubules, structures essential for cell division. By inhibiting these targets, Eribulin may interfere with cancer cell proliferation.
Eribulin is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The company is conducting clinical research on Eribulin for the treatment of metastatic breast cancer.
Eribulin is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 2 trial is actively recruiting participants to evaluate Eribulin in patients with metastatic breast cancer.
Eribulin is being studied in one active Phase 2 clinical trial with the identifier NCT04986579. This trial, titled 'Scalp Cooling in MBC,' is investigating Eribulin in patients with metastatic breast cancer and chemotherapy-induced alopecia. The study is recruiting 120 participants in the United States.
Yes, Eribulin is also known as Eribulin Mesylate Injection. These names refer to the same drug product. Eribulin Mesylate Injection is the formulation name, while Eribulin is the generic drug name used in clinical and research contexts.